Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo

Refractory acute myeloid leukemia (AML) remains an incurable malignancy despite the clinical use of novel targeted therapies, new antibody-based therapies, and cellular therapeutics. Here, we describe the preclinical development of a novel cell therapy that targets the antigen CLEC12A with a biparat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rennert, Paul D., Dufort, Fay J., Su, Lihe, Sanford, Tom, Birt, Alyssa, Wu, Lan, Lobb, Roy R., Ambrose, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Models and Technologies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398100/
https://www.ncbi.nlm.nih.gov/pubmed/34253594
http://dx.doi.org/10.1158/1535-7163.MCT-20-1030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398100/
https://www.ncbi.nlm.nih.gov/pubmed/34253594
http://dx.doi.org/10.1158/1535-7163.MCT-20-1030

Ejemplares similares